Evidence map›Paper›PMID 40254721›Full record

ArticleInfluenza and other respiratory viruses2025

Estimated Incidence of Hospitalisations and Deaths Attributable to Respiratory Syncytial Virus Infections in Adults in Australia Between 2010 and 2019.

Zirke Wiid, Caihua Liang, Robin Bruyndonckx, Lauren Mason, Aleksandra Polkowska-Kramek, Pimnara Peerawaranun, Mikel Esnaola, Worku Biyadgie Ewnetu, Somsuvro Basu, David Witcombe and 2 more

Abstract read
In one paragraph

Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zirke WiidPfizer Australia, Sydney, Australia.
Caihua LiangPfizer Inc., New York City, USA.
Robin BruyndonckxP95 Epidemiology & Pharmacovigilance, Leuven, Belgium.
Lauren MasonP95 Epidemiology & Pharmacovigilance, Leuven, Belgium.
Aleksandra Polkowska-KramekP95 Epidemiology & Pharmacovigilance, Leuven, Belgium.ORCID 0000-0003-0148-7183
Pimnara PeerawaranunP95 Epidemiology & Pharmacovigilance, Leuven, Belgium.
Mikel EsnaolaP95 Epidemiology & Pharmacovigilance, Leuven, Belgium.
Worku Biyadgie EwnetuP95 Epidemiology & Pharmacovigilance, Leuven, Belgium.ORCID 0000-0002-3650-2016
Somsuvro BasuP95 Epidemiology & Pharmacovigilance, Leuven, Belgium.
David WitcombePfizer Australia, Sydney, Australia.
Bradford D GessnerPfizer Inc., New York City, USA.
Elizabeth BegierPfizer Inc., Dublin, Ireland.

Funding

Pfizer
6 · The paper itself

Abstract

backgroundRespiratory syncytial virus (RSV) morbidity and mortality in adults are often underestimated due to nonspecific symptoms, limited standard-of-care testing and lower diagnostic testing sensitivity compared with children. To accurately evaluate the RSV disease burden among adults in Australia, we conducted a model-based study to estimate RSV-attributable cardiorespiratory hospitalisation incidence and mortality rate.

methodsA quasi-Poisson regression model was used to estimate RSV-attributable cardiorespiratory, respiratory and cardiovascular events, using weekly hospitalisation and mortality data from 2010 to 2019, accounting for periodic and aperiodic time trends and viral activity and allowing for potential overdispersion. The time-series model compared the variability in confirmed RSV events alongside variability in all-cause cardiorespiratory events identified from ICD-10-AM codes to estimate the number of RSV-attributable events, including undiagnosed RSV-related events.

resultsRSV-attributable incidence of cardiorespiratory hospitalisations increased with age and was highest among adults ≥ 65 years (329.5-386.6 cases per 100,000 person-years), nine times higher than in adults 18-64 years. The estimated incidence of RSV-attributable respiratory hospitalisations in adults ≥65 years (219.7-247.8 cases per 100,000 person-years) was 35-fold higher than in adults 18-64 years. RSV-attributable deaths accounted for 4% to 6% of cardiorespiratory deaths in adults ≥ 65 years, with RSV-attributable mortality rates ranging from 65.6 to 77.6 deaths per 100,000 person-years and respiratory mortality rates ranging from 20.3 to 24.0 deaths per 100,000 person-years, both 70-fold higher than in adults 18-64 years.

conclusionsThis study identified substantial RSV-associated morbidity and mortality among Australian adults and is the first study to report RSV-attributable mortality rates for Australia that account for untested events.

Indexed as

HospitalizationRespiratory Syncytial Virus InfectionsAdolescentAdultAgedAged, 80 and overAustraliaFemaleHumansIncidenceMaleMiddle AgedRespiratory Syncytial Virus, HumanYoung AdultadultsAustraliahospitalisationmortalityquasi‐Poisson regressionrespiratory syncytial virustime‐series modelling

Identifiers

PMID40254721
PMCPMC12009690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.